Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6354562 | 0.93 | PTGS2 (0.46) | PTGESPTPRCPTGS1PDPK1EPHX2 | |
| SCHEMBL6345063 | 0.89 | RAB9A (0.43) | PTPRCMEN1KMT2APTGS2 | |
| SCHEMBL6353442 | 0.88 | CRACR2A (0.43) | KMT2ACRACR2APTGS2 | |
| SCHEMBL6354558 | 0.87 | KMT2A (0.44) | KMT2APTGS2 | |
| SCHEMBL6352335 | 0.84 | JAK2 (0.44) | F2RMEN1KMT2A | |
| SCHEMBL6342495 | 0.84 | IKBKB (0.51) | MEN1KMT2A | |
| SCHEMBL6343697 | 0.81 | PTGS2 (0.46) | PTGS1KMT2AEPHX2PTGS2 | |
| SCHEMBL6342809 | 0.81 | PTGS2 (0.49) | CRACR2APTGS2 | |
| SCHEMBL6626661 | 0.81 | PTGS2 (0.46) | PTGS1F2RPDPK1KCNK3KCNK9 | |
| SCHEMBL6340626 | 0.80 | KMT2A (0.55) | PTGS1KMT2AEPHX2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1438293-A2 | SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-07-21 | — | — | EP | claimed |
| US-20030125361-A1 | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-07-03 | — | — | US | claimed |
| WO-2003027075-A2 | SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | claimed |
| US-6849653-B2 | 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis | PHARMACIA CORPORATION (US) | 2005-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125361-A1 | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation | IRAK4, NLRP3, CXCL8 | PTGES 38/4885PTPRC 400/4885PTGS1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.